Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: EST001
MIFTS: 49

Estrogen-Receptor Positive Breast Cancer

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Estrogen-Receptor Positive Breast Cancer

About this section

MalaCards integrated aliases for Estrogen-Receptor Positive Breast Cancer:

Name: Estrogen-Receptor Positive Breast Cancer 12 15 17

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0060075
Sources

Summaries for Estrogen-Receptor Positive Breast Cancer

About this section
Disease Ontology : 12 A breast cancer that is characterized by the presence of estrogen receptors.

MalaCards based summary : Estrogen-Receptor Positive Breast Cancer is related to mammographic density and tubular adenocarcinoma. An important gene associated with Estrogen-Receptor Positive Breast Cancer is HSPB8 (Heat Shock Protein Family B (Small) Member 8), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Palbociclib and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Estrogen-Receptor Positive Breast Cancer

About this section

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 378)
# Related Disease Score Top Affiliating Genes
1 mammographic density 31.2 PGR ESR1 CYP19A1
2 tubular adenocarcinoma 31.0 PGR ESR1 ERBB2 EGFR
3 cribriform carcinoma 31.0 PGR ESR1 ERBB2
4 vaginal discharge 30.9 PGR ESR1 CYP19A1
5 endometrial disease 30.9 PGR ESR1 CYP19A1
6 papillary adenocarcinoma 30.8 TP53 PGR ERBB2 BRCA1
7 postmenopausal atrophic vaginitis 30.8 ESR1 CYP19A1
8 endometrial hyperplasia 30.7 TP53 PGR NCOA3 ESR1 CYP19A1 CCND1
9 mucinous adenocarcinoma 30.7 TP53 PGR ESR1 ERBB2 EGFR
10 bone resorption disease 30.6 ESR1 CYP19A1 AKT1
11 fallopian tube carcinoma 30.5 TP53 PGR MYC ESR1 ERBB2 BRCA1
12 female breast cancer 30.4 TP53 PGR ESR1 ERBB2 CYP19A1 BRCA1
13 hypertrophy of breast 30.4 TP53 PIK3CA PGR ESR1 ERBB2 CYP19A1
14 exanthem 30.4 MTOR ERBB2 EGFR AKT1
15 breast disease 30.3 TP53 PGR MIR125A ESR1 ERBB2 CYP19A1
16 estrogen-receptor negative breast cancer 30.3 SRC PGR FOXA1 ESR1 ERBB2 EGFR
17 thyroid carcinoma 30.2 TP53 PIK3CA AKT1
18 insulin-like growth factor i 30.2 ESR1 EGFR AKT1
19 tuberous sclerosis 30.2 TP53 PIK3CA MYC MTOR AKT1
20 breast ductal carcinoma 30.0 TP53 PGR ESR1 ERBB2 EGFR CYP19A1
21 osteoporosis 30.0 TP53 PGR ESR1 CYP19A1 AR AKT1
22 sporadic breast cancer 29.9 TP53 PGR MYC ESR1 ERBB2 EGFR
23 breast adenocarcinoma 29.7 TP53 PIK3CA PGR MYC ESR1 ERBB2
24 in situ carcinoma 29.6 TP53 PGR MYC ESR1 ERBB2 EGFR
25 adenocarcinoma 29.6 TP53 PIK3CA MYC FGFR2 ERBB2 EGFR
26 thymoma 29.6 TP53 PIK3CA MTOR MIR125A EGFR CCND1
27 ductal carcinoma in situ 29.3 TP53 PIK3CA PGR MYC ESR1 ERBB2
28 breast cancer 28.7 TP53 SRC PIK3CA PGR NCOA3 MYC
29 lung cancer susceptibility 3 28.7 TP53 SRC PIK3CA MYC MTOR MIR125A
30 hepatocellular carcinoma 28.6 TP53 SRC PIK3CA MYC MTOR MIR125A
31 endometrial cancer 28.4 TP53 PIK3CA PGR NCOA3 MYC MTOR
32 esophageal leukoplakia 10.7 TP53 CCND1
33 bartholin's gland adenoid cystic carcinoma 10.7 PGR ESR1
34 chronic tympanitis 10.7 PGR ESR1
35 granulomatous endometritis 10.7 PGR ESR1
36 scirrhous adenocarcinoma 10.7 PGR ERBB2
37 liver adenomatosis 10.7 PGR AR
38 gastric papillary adenocarcinoma 10.6 TP53 ERBB2
39 lung leiomyoma 10.6 PGR ESR1
40 glassy cell carcinoma of the cervix 10.6 PGR ESR1 ERBB2
41 vulvar syringoma 10.6 PGR ESR1
42 synchronous bilateral breast carcinoma 10.6 PGR BRCA1
43 pancreatic foamy gland adenocarcinoma 10.6 TP53 CCND1
44 trigonitis 10.6 PGR ESR1
45 bartholin's gland adenoma 10.6 TP53 PGR ESR1
46 bartholin's gland benign neoplasm 10.6 TP53 PGR ESR1
47 vestibular gland benign neoplasm 10.6 TP53 PGR ESR1
48 familiar ovarian carcinoma 10.6 PIK3CA BRCA1
49 breast papillary carcinoma 10.6 PGR ESR1 ERBB2
50 ovarian seromucinous carcinoma 10.6 TP53 PGR ESR1

Graphical network of the top 20 diseases related to Estrogen-Receptor Positive Breast Cancer:



Diseases related to Estrogen-Receptor Positive Breast Cancer
Sources

Symptoms & Phenotypes for Estrogen-Receptor Positive Breast Cancer

About this section

GenomeRNAi Phenotypes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

26 (show top 50) (show all 70)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.86 EGFR MTOR PIK3CA
2 Decreased viability GR00107-A-1 10.86 HSPB8
3 Decreased viability GR00221-A-1 10.86 HSPB8 AKT1 EGFR ESR1 MTOR MYC
4 Decreased viability GR00221-A-2 10.86 BRCA1 AKT1 ESR1 PIK3CA
5 Decreased viability GR00221-A-3 10.86 BRCA1 AKT1 MYC ERBB2
6 Decreased viability GR00221-A-4 10.86 HSPB8 AKT1 EGFR ESR1 MTOR PIK3CA
7 Decreased viability GR00301-A 10.86 BRCA1 FGFR2 HSPB8 SRC
8 Decreased viability GR00342-S-1 10.86 FGFR2 MTOR
9 Decreased viability GR00342-S-2 10.86 FGFR2 MTOR
10 Decreased viability GR00342-S-3 10.86 FGFR2
11 Decreased viability GR00402-S-2 10.86 BRCA1 FGFR2 HSPB8 SRC AKT1 EGFR
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-1 10.37 FOXA1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.37 MTOR
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.37 BRCA1 FOXA1 PIK3CA
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.37 CCND1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.37 BRCA1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.37 CCND1
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.37 BRCA1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.37 CCND1 FOXA1 PIK3CA
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.37 FOXA1
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.37 BRCA1 CCND1 FOXA1 MTOR PIK3CA
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 10.37 BRCA1
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.37 CCND1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.23 MTOR
25 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.23 FOXA1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.23 CCND1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.23 FOXA1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.23 FOXA1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-144 10.23 MYC
30 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.23 CCND1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.23 PIK3CA
32 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.23 AKT1 MTOR PIK3CA CCND1 FOXA1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.23 ERBB2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.23 ERBB2 CCND1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.23 PIK3CA
36 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.23 ERBB2
37 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10.23 MTOR MYC
38 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.23 AKT1 PIK3CA CCND1 FOXA1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.23 MYC
40 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.23 FOXA1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.23 PIK3CA
42 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.23 CCND1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.23 FOXA1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.23 ERBB2
45 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.23 CCND1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.23 CCND1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.23 CCND1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.23 FOXA1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.23 MYC
50 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.23 MYC CCND1

MGI Mouse Phenotypes related to Estrogen-Receptor Positive Breast Cancer:

45 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.55 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
2 endocrine/exocrine gland MP:0005379 10.52 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
3 behavior/neurological MP:0005386 10.5 AKT1 AR BRCA1 CCND1 CYP19A1 ERBB2
4 cardiovascular system MP:0005385 10.5 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
5 growth/size/body region MP:0005378 10.49 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
6 homeostasis/metabolism MP:0005376 10.49 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
7 immune system MP:0005387 10.48 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
8 embryo MP:0005380 10.44 AKT1 AR BRCA1 EGFR ERBB2 ESR1
9 integument MP:0010771 10.44 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
10 mortality/aging MP:0010768 10.42 AKT1 AR BRCA1 CCND1 EGFR ERBB2
11 adipose tissue MP:0005375 10.41 AKT1 AR BRCA1 CYP19A1 EGFR ESR1
12 hematopoietic system MP:0005397 10.41 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
13 digestive/alimentary MP:0005381 10.38 AR BRCA1 CCND1 CYP19A1 EGFR ERBB2
14 muscle MP:0005369 10.35 AKT1 AR BRCA1 CYP19A1 EGFR ERBB2
15 neoplasm MP:0002006 10.33 AKT1 AR BRCA1 CCND1 EGFR ERBB2
16 nervous system MP:0003631 10.28 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
17 craniofacial MP:0005382 10.26 AR CCND1 EGFR ERBB2 FGFR2 MYC
18 limbs/digits/tail MP:0005371 10.22 AR BRCA1 EGFR ERBB2 ESR1 FGFR2
19 normal MP:0002873 10.21 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
20 liver/biliary system MP:0005370 10.16 AKT1 AR CYP19A1 EGFR ESR1 FGFR2
21 hearing/vestibular/ear MP:0005377 10.05 CYP19A1 EGFR FGFR2 MYC NCOA3 TP53
22 reproductive system MP:0005389 10.03 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
23 no phenotypic analysis MP:0003012 10.01 EGFR ESR1 FGFR2 MTOR MYC PGR
24 pigmentation MP:0001186 9.92 AR BRCA1 CYP19A1 EGFR FGFR2 MYC
25 renal/urinary system MP:0005367 9.91 AR BRCA1 CYP19A1 EGFR ESR1 FGFR2
26 respiratory system MP:0005388 9.7 AKT1 BRCA1 CCND1 EGFR ERBB2 ESR1
27 skeleton MP:0005390 9.53 AKT1 AR BRCA1 CCND1 CYP19A1 EGFR
Sources

Drugs & Therapeutics for Estrogen-Receptor Positive Breast Cancer

About this section

Drugs for Estrogen-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Palbociclib Approved, Investigational Phase 4 571190-30-2 11431660 5005498 5330286
2
Epirubicin Approved Phase 4 56420-45-2 41867
3
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
4
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
5
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
6 Alkylating Agents Phase 4
7 Topoisomerase Inhibitors Phase 4
8
Methyltestosterone Approved Phase 3 58-18-4 6010
9
Testosterone Approved, Experimental, Investigational Phase 3 58-22-0, 481-30-1 6013 10204
10
Testosterone enanthate Approved Phase 3 315-37-7 9416
11
Testosterone undecanoate Approved, Investigational Phase 3 5949-44-0
12
Fluorouracil Approved Phase 3 51-21-8 3385
13
Norepinephrine Approved Phase 3 51-41-2 439260
14
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
15
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
16
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
17
Tamoxifen Approved Phase 3 10540-29-1 2733526
18
Metformin Approved Phase 3 657-24-9 14219 4091
19
Goserelin Approved Phase 3 65807-02-5, 1233494-97-7 47725 5311128
20
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
21
Sodium citrate Approved, Investigational Phase 3 68-04-2
22
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
23
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
24
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
25
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
26
Lenograstim Approved, Investigational Phase 3 135968-09-1
27
Leuprolide Approved, Investigational Phase 3 53714-56-0 3911 657181
28
Lapatinib Approved, Investigational Phase 3 231277-92-2, 388082-78-8 208908 9941095
29
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
30
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
31
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
32
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
33
Capecitabine Approved, Investigational Phase 2, Phase 3 154361-50-9 60953
34
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
35
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
36
Ergocalciferol Approved, Nutraceutical Phase 2, Phase 3 50-14-6 5280793
37
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 1406-16-2
38
Vitamin D3 Approved, Nutraceutical Phase 2, Phase 3 67-97-0 6221 5280795
39 Neurotransmitter Agents Phase 3
40 Omega 3 Fatty Acid Phase 3
41 Androgens Phase 3
42 Anabolic Agents Phase 3
43 Testosterone 17 beta-cypionate Phase 3
44 Analgesics Phase 3
45 Dopamine Agents Phase 3
46 Psychotropic Drugs Phase 3
47 Duloxetine Hydrochloride Phase 3
48 Serotonin and Noradrenaline Reuptake Inhibitors Phase 3
49 Antidepressive Agents Phase 3
50 Mitogens Phase 3

Interventional clinical trials:

(show top 50) (show all 146)
# Name Status NCT ID Phase Drugs
1 Phase II Open Label Study of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic, Estrogen Receptor Positive Breast Cancer, After Failure of Tamoxifen and/or Anastrozole and/or Letrozole and/or Fulvestrant and/or Exemestane Completed NCT01231659 Phase 4 Everolimus + Letrozole
2 Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy for Postmenopausal Estrogen Receptor-positive Breast Cancer: a Prospective Randomized Controlled Double-blind Phase IV Trial Not yet recruiting NCT04137640 Phase 4 palbociclib combined with letrozole;epirubicin combined with cyclophosphamide and sequential docetaxel
3 A Prospective, Randomized, Open-label, Multicenter Study Evaluating the Effects on Cognitive Functions of Adjuvant Endocrine Therapy in Postmenopausal Women With Breast Cancer. Unknown status NCT00893061 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
4 A Phase III Study Comparing Anastrozole, Letrozole and Exemestane, Upfront (for 5 Years) or Sequentially (for 3 Years After 2 Years of Tamoxifen), as Adjuvant Treatment of Postmenopausal Patients With Endocrine-responsive Breast Cancer Unknown status NCT00541086 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
5 ARTemis - Avastin Randomized Trial With Neo-Adjuvant Chemotherapy for Patients With Early Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
6 Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias Completed NCT01573442 Phase 3 testosterone
7 Randomized Double-blind Study to Compare Two Neo-adjuvant Treatments: an Anti-aromatase vs SERM for Postmenopausal Women With ER+ Breast Adenocarcinoma: Effect on Intermediate Predictive Biological Response to Treatment. Completed NCT00949598 Phase 3 letrozole;tamoxifen citrate
8 Ovarian Protection Trial In Premenopausal Breast Cancer Patients [OPTION] Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
9 A Neoadjuvant Study of Chemotherapy Versus Endocrine Therapy in Postmenopausal Patients With Primary Breast Cancer Completed NCT00963729 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil;letrozole
10 A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer Completed NCT01598298 Phase 3 duloxetine hydrochloride
11 A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
12 S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III Completed NCT01385137 Phase 3
13 Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial Recruiting NCT03011684 Phase 3 Tamoxifen;Letrozole
14 Efficacy, Tolerability, and Safety of Palbociclib Combined With an Aromatase Inhibitor in Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Locally Advanced Breast Cancer Recruiting NCT04047758 Phase 3 Palbociclib + Letrozole;Letrozole
15 Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study Active, not recruiting NCT01953588 Phase 3 fulvestrant;anastrozole
16 A Phase III Trial of Chidamide in Combination With Exemestane in Patients With Hormone Receptor-Positive Advanced Breast Cancer (ACE) Active, not recruiting NCT02482753 Phase 3 Chidamide;exemestane;placebo
17 A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer Active, not recruiting NCT00066703 Phase 3 exemestane;tamoxifen;triptorelin
18 International Breast Cancer Intervention Study Active, not recruiting NCT00078832 Phase 3 anastrozole;placebo
19 A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
20 A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer Active, not recruiting NCT00066690 Phase 3 Exemestane;Tamoxifen;Triptorelin
21 A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer Active, not recruiting NCT00265759 Phase 3 anastrozole;exemestane;letrozole
22 A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer Active, not recruiting NCT01101438 Phase 3 metformin hydrochloride
23 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer Active, not recruiting NCT01674140 Phase 3 anastrozole;everolimus;exemestane;goserelin acetate;letrozole;leuprolide acetate;tamoxifen citrate
24 Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial Active, not recruiting NCT00310180 Phase 3 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate
25 Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer Active, not recruiting NCT00070564 Phase 3 AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
26 A Phase III Trial of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer Active, not recruiting NCT01349322 Phase 3
27 Effect of Perioperative AntiHER-2 Therapy on Early Breast Cancer Study - Biological Phase (EPHOS-B) Active, not recruiting NCT01104571 Phase 3 lapatinib ditosylate
28 MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy): A Prospective, Randomized Study Comparing the 70-Gene Signature With the Common Clinical-Pathological Criteria in Selecting Patients for Adjuvant Chemotherapy in Breast Cancer With 0 to 3 Positive Nodes Active, not recruiting NCT00433589 Phase 3 anthracycline-based;docetaxel and capecitabine
29 A Randomized Controlled Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP） Enrolling by invitation NCT03137368 Phase 3 Exemestane Tablets;Tamoxifen
30 Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients Suspended NCT02137837 Phase 3 Fulvestrant;Anastrozole;Everolimus;Placebo - Anastrozole;Placebo - Everolimus
31 Randomized Phase II/III Study of Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic Estrogen Receptor Positive Breast Cancer Terminated NCT00684216 Phase 2, Phase 3 capecitabine;hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
32 Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients Terminated NCT01809171 Phase 2, Phase 3 Vitamin D3;Placebo
33 A Phase II Study of the Efficacy and Tolerability of Bicalutamide Plus Aromatase Inhibitors in Estrogen Receptor(+)/Androgen Receptor(+)/HER2(-) Metastatic Breast Cancer Unknown status NCT02910050 Phase 2 Bicalutamide;Aromatase Inhibitor
34 A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen Unknown status NCT01124695 Phase 2 tamoxifen citrate
35 Response to Neoadjuvant Treatment With Anti-aromatase Anastrozole and Anti-estrogen Fulvestrant: a Randomized Phase II Study in Postmenopausal Patients With Hormone-sensitive Nonmetastatic Breast Cancer and an Exploratory Study of Molecular Signatures of Response Unknown status NCT00871858 Phase 2 anastrozole;fulvestrant
36 Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Post-menopausal, Estrogen Receptor Positive, Breast Cancer Patients Unknown status NCT00954135 Phase 2 letrozolo+cyclophosphamide;letrozolo+sorafenib+cyclophosphamide
37 A Randomized Phase II Study of Fulvestrant in Combination With the Dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant Alone in Estrogen Receptor-positive Advanced or Metastatic Breast Cancer Unknown status NCT02216786 Phase 2 AZD2014;Everolimus;Fulvestrant
38 A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer Unknown status NCT01142401 Phase 2 Bortezomib;Fulvestrant
39 Randomised Phase II Study of Metronomic Chemotherapy Plus the Same Aromatase Inhibitor Compared to Metronomic Chemotherapy Alone in Women With Hormone Receptor Positive, Her-2 Non-Overexpressing Advanced Breast Cancer Whose Disease Has Progressed While Receiving an Aromatase Inhibitor, Correlating Response With Circulating Endothelial Progenitor Cells, VEGF and VEGFR Unknown status NCT00687648 Phase 2 anastrozole;cyclophosphamide;exemestane;letrozole;methotrexate;prednisolone
40 Pilot / Phase II Randomised, Double Blind, Placebo Controlled Multicenter Study With Biomarker Evaluation of Neoadjuvant Exemestane in Combination With Sunitinib in Post-menopausal Women With Hormone- Sensitive, Her-2 Negative Primary Breast Cancer. Unknown status NCT00931450 Phase 1, Phase 2 exemestane;sunitinib malate
41 Single Arm Phase 2 Study of Metformin and Simvastatin in Addition to Fulvestrant in Metastatic Estrogen Receptor Positive Breast Cancer Unknown status NCT03192293 Phase 2 Metformin/Simvastatin/Fulvestrant
42 A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI) Completed NCT00767520 Phase 2 Exemestane + Dasatinib;Exemestane + Placebo
43 A Randomized, Open-Label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX®) 500 mg With Fulvestrant (FASLODEX®) 250 mg When Given as Neoadjuvant Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0). Completed NCT00093002 Phase 2 Fulvestrant
44 A Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Study Assessing the Value of Adding Everolimus to Letrozole as Preoperative Therapy of Primary Breast Cancer in Postmenopausal Women Completed NCT00107016 Phase 2 RAD001, Letrozole 2.5mg;Letrozole 2.5mg
45 A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment With a Non-Steroidal Aromatase Inhibitor Completed NCT00676663 Phase 2 entinostat;exemestane;Placebo
46 Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer Completed NCT01589367 Phase 2 Metformin;Placebo
47 A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients Completed NCT01605396 Phase 2 Ridaforolimus;Dalotuzumab;Exemestane
48 Phase II Randomized Trial of Mugard Compared With Best Supportive Care for Prevention and Treatment of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy. Completed NCT02015559 Phase 2 mucoadhesive oral wound rinse
49 Open Label, Phase II Trial of Neoadjuvant TAK-228 Plus Tamoxifen in Patients With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Completed NCT02988986 Phase 2 TAK-228;Tamoxifen
50 RED CLOVER EXTRACT (PROMENSIL) AND LIFESTYLE CHANGES TO CONTRAST MENOPAUSAL SYMPTOMS IN PREMENOPAUSAL WOMEN WITH HORMONE-SENSITIVE BREAST CANCER RECEIVING ADJUVANT ANTI-ESTROGEN THERAPY Completed NCT03844685 Phase 2 Promensil;Placebo Oral Tablet

Search NIH Clinical Center for Estrogen-Receptor Positive Breast Cancer

Sources

Genetic Tests for Estrogen-Receptor Positive Breast Cancer

About this section
Sources

Anatomical Context for Estrogen-Receptor Positive Breast Cancer

About this section

MalaCards organs/tissues related to Estrogen-Receptor Positive Breast Cancer:

40
Breast, Bone, Lymph Node, Lung, Thyroid, Testes, B Cells
Sources

Publications for Estrogen-Receptor Positive Breast Cancer

About this section

Articles related to Estrogen-Receptor Positive Breast Cancer:

(show top 50) (show all 1195)
# Title Authors PMID Year
1
BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer. 61
31469414 2020
2
Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study. 61
31918322 2020
3
Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. 61
31518174 2020
4
Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older. 61
31811505 2020
5
Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. 61
31710162 2020
6
Overcoming Tamoxifen-Resistance in Estrogen Receptor Positive Breast Cancer Using the Novel Thiosemicarbazone Anti-Cancer Agent, DpC. 61
31975484 2020
7
Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis. 61
31733575 2020
8
Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer. 61
31942683 2020
9
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. 61
31932695 2020
10
MAGI1, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer. 61
31963297 2020
11
Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors. 61
31037379 2020
12
Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer. 61
31721572 2020
13
CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree? 61
31690650 2020
14
Synthesis, Cytotoxicity and Antimicrobial Evaluation of New Coumarin-Tagged β-Lactam Triazole Hybrid. 61
31788939 2020
15
Untapped "-omics": the microbial metagenome, estrobolome, and their influence on the development of breast cancer and response to treatment. 61
31646389 2020
16
BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer. 61
31409615 2019
17
Managing menopausal symptoms after cancer. 61
31433675 2019
18
Antiproliferative activity and p53 upregulation effects of chalcones on human breast cancer cells. 61
31117836 2019
19
Bone health in women with breast cancer. 61
30896255 2019
20
Late Recurrences After Estrogen Receptor-Positive Breast Cancer. 61
31830232 2019
21
Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. 61
31859350 2019
22
The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis. 61
31522958 2019
23
Anti-proliferative transcriptional effects of medroxyprogesterone acetate in estrogen receptor positive breast cancer cells are predominantly mediated by the progesterone receptor. 61
31805393 2019
24
Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. 61
31928692 2019
25
18F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with 18F-FDG PET/CT. 61
31337657 2019
26
The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane. 61
31891807 2019
27
Omission of radiation therapy following breast conservation in older (≥70 years) women with T1-2N0 triple-negative breast cancer. 61
31273872 2019
28
Involution of Breast Lobules, Mammographic Breast Density and Prognosis Among Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer Patients. 61
31689948 2019
29
Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer. 61
31675993 2019
30
Hypofractionated radiation in older women with breast cancer. 61
31359556 2019
31
Inhibition of tamoxifen's therapeutic effects by emodin in estrogen receptor-positive breast cancer cell lines. 61
31742207 2019
32
Tumor microenvironmental growth factors induce long-term estrogen deprivation resistance in breast cancer. 61
31119683 2019
33
DC-SCRIPT deficiency delays mouse mammary gland development and branching morphogenesis. 61
31265831 2019
34
Tamoxifen and Sulphoraphane for the breast cancer management: A synergistic nanomedicine approach. 61
31454641 2019
35
Identification of differentially expressed gene sets using the Generalized Berk-Jones statistic. 61
31062858 2019
36
SIRT4 enhances the sensitivity of ER-positive breast cancer to tamoxifen by inhibiting the IL-6/STAT3 signal pathway. 61
31573734 2019
37
Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer. 61
31211741 2019
38
RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype. 61
31604910 2019
39
DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-Positive Breast Cancer Following Endocrine Therapy. 61
31387918 2019
40
Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report. 61
31640597 2019
41
Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling. 61
30941654 2019
42
Impact of the 21-gene recurrence score assay on chemotherapy decision making and outcomes for breast cancer patients with four or more positive lymph nodes. 61
31700882 2019
43
Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. 61
31361400 2019
44
Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report. 61
31517852 2019
45
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. 61
31439820 2019
46
Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer. 61
31669266 2019
47
Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. 61
31479144 2019
48
Association between perceived benefits and receipt of radiotherapy among older breast cancer patients. 61
31478585 2019
49
Selective oestrogen receptor degraders in breast cancer: a review and perspectives. 61
31335829 2019
50
Removal of Serum Lipids and Lipid-Derived Metabolites to Investigate Breast Cancer Cell Biology. 61
30919589 2019
Sources

Variations for Estrogen-Receptor Positive Breast Cancer

About this section
Sources

Expression for Estrogen-Receptor Positive Breast Cancer

About this section
Search GEO for disease gene expression data for Estrogen-Receptor Positive Breast Cancer.
Sources

Pathways for Estrogen-Receptor Positive Breast Cancer

About this section

Pathways related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 157)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 14.32 TP53 SRC PIK3CA PGR NCOA3 MYC
2
ERK Signaling 63
Show member pathways
 13.97 TP53 SRC MYC MTOR FGFR2 ESR1
3
Gene Expression 65
Show member pathways
 13.94 TP53 PGR MYC MTOR ESR1 ERBB2
4
GPCR Pathway 63
Show member pathways
 13.85 TP53 SRC NCOA3 MYC FGFR2 ESR1
5
PEDF Induced Signaling 63
Show member pathways
 13.8 TP53 SRC NCOA3 MYC MTOR FGFR2
6
TGF-Beta Pathway 63
Show member pathways
 13.7 TP53 SRC PIK3CA MYC MTOR FGFR2
7
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.58 TP53 SRC PIK3CA MTOR FGFR2 ERBB2
8
Akt Signaling 63
Show member pathways
 13.57 TP53 SRC MTOR FGFR2 ERBB2 EGFR
9
Cytokine Signaling in Immune system 65
Show member pathways
 13.52 TP53 SRC PIK3CA MYC FGFR2 ERBB2
10
IL-2 Pathway 63
Show member pathways
 13.36 TP53 SRC MYC MTOR ERBB2 EGFR
11
GAB1 signalosome 65
Show member pathways
 13.28 TP53 SRC PIK3CA MTOR FGFR2 ERBB2
12
Toll-like Receptor Signaling Pathway 1 36
Show member pathways
 13.26 TP53 SRC PIK3CA MYC EGFR CCND1
13
Phospholipase-C Pathway 63
Show member pathways
 13.18 TP53 SRC MTOR FGFR2 EGFR AKT1
14
PI3K-Akt signaling pathway 36
Show member pathways
 13.13 TP53 PIK3CA MYC MTOR FGFR2 ERBB2
15
Human cytomegalovirus infection 36
Show member pathways
 13.11 TP53 SRC PIK3CA MYC MTOR EGFR
16
TNFR1 Pathway 63
Show member pathways
 13.07 TP53 SRC PIK3CA MTOR EGFR AKT1
17
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.04 SRC PIK3CA MTOR ERBB2 EGFR AKT1
18
NFAT and Cardiac Hypertrophy 63
Show member pathways
 13.04 SRC PIK3CA MTOR FGFR2 ERBB2 EGFR
19
Focal Adhesion 1 36
Show member pathways
 13.03 SRC PIK3CA ERBB2 EGFR CCND1 AKT1
20
Endometrial cancer 36
Show member pathways
 12.96 TP53 SRC PIK3CA MYC MTOR FGFR2
21
MAPK signaling pathway 36 1
12.92 TP53 MYC FGFR2 ERBB2 EGFR AKT1
22
Herpes simplex virus 1 infection 36
12.91 TP53 SRC PIK3CA MTOR AKT1
23
Pathways in cancer 36
12.91 TP53 PIK3CA NCOA3 MYC MTOR FGFR2
24
Development HGF signaling pathway 22
Show member pathways
 12.9 TP53 SRC PIK3CA MTOR ESR1 ERBB2
25
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.89 PIK3CA MYC MTOR CCND1 AKT1
26
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.89 TP53 SRC PIK3CA MTOR FGFR2 ERBB2
27
Ras signaling pathway 36
Show member pathways
 12.86 SRC PIK3CA FGFR2 EGFR AKT1
28
Relaxin signaling pathway 36
Show member pathways
 12.83 SRC PIK3CA PGR NCOA3 MTOR ESR1
29
Chks in Checkpoint Regulation 63
Show member pathways
 12.82 TP53 MYC ESR1 CCND1 BRCA1
30
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.82 SRC PIK3CA MTOR EGFR CCND1 AKT1
31
Immune response IL-23 signaling pathway 22
Show member pathways
 12.77 TP53 SRC PIK3CA MYC ERBB2 EGFR
32
ErbB signaling pathway 1 36
Show member pathways
 12.71 TP53 SRC PIK3CA MYC MTOR FGFR2
33
Notch Signaling Pathway (WikiPathways) 1
Show member pathways
 12.69 SRC MYC MTOR CCND1 AKT1
34
mTOR signaling pathway (KEGG) 64
Show member pathways
 12.68 TP53 PIK3CA MTOR FGFR2 ERBB2 EGFR
35
MicroRNAs in cancer 36
12.67 TP53 PIK3CA MYC MTOR MIR125A ERBB2
36
Development ERBB-family signaling 22
Show member pathways
 12.66 TP53 SRC PIK3CA MYC MTOR ERBB2
37
Prolactin Signaling Pathway 1 36
Show member pathways
 12.65 SRC PIK3CA MYC MTOR ESR1 ERBB2
38
Apoptosis Pathway 70
Show member pathways
 12.62 TP53 PIK3CA MTOR FGFR2 ERBB2 EGFR
39
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.59 TP53 PIK3CA MTOR CCND1 AKT1
40
Development IGF-1 receptor signaling 22
Show member pathways
 12.59 TP53 PIK3CA MYC MTOR CCND1 AKT1
41
Shigellosis 36
12.57 TP53 SRC PIK3CA MTOR EGFR AKT1
42
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.56 SRC PIK3CA ESR1 BRCA1 AKT1
43
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.55 SRC PIK3CA MTOR FGFR2 ERBB2 EGFR
44
JAK-STAT signaling pathway (KEGG) 36
Show member pathways
 12.53 PIK3CA MYC MTOR EGFR CCND1 AKT1
45
Development FGFR signaling pathway 22
Show member pathways
 12.52 SRC PIK3CA FGFR2 AKT1
46
Human T-cell leukemia virus 1 infection 36
12.51 TP53 PIK3CA MYC CCND1 AKT1
47
DNA Damage Response 1
Show member pathways
 12.49 TP53 MYC CCND1 BRCA1
48
Development A3 receptor signaling 22
Show member pathways
 12.49 SRC PIK3CA MYC CCND1 AKT1
49
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.48 PIK3CA NCOA3 ESR1 ERBB2 EGFR CCND1
50
Oocyte meiosis 36
Show member pathways
 12.47 PIK3CA PGR AR AKT1
Sources

GO Terms for Estrogen-Receptor Positive Breast Cancer

About this section

Cellular components related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.2 TP53 SRC PIK3CA PGR NCOA3 MTOR
2 nucleus GO:0005634 10.06 TP53 SRC PGR NCOA3 MYC MTOR
3 nuclear chromatin GO:0000790 9.8 TP53 PGR NCOA3 MYC FOXA1 ESR1
4 nucleoplasm GO:0005654 9.77 TP53 PGR NCOA3 MYC MTOR HSPB8
5 protein-containing complex GO:0032991 9.28 TP53 NCOA3 MYC MTOR ESR1 EGFR

Biological processes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10.19 TP53 MYC FOXA1 FGFR2 ESR1 CCND1
2 regulation of transcription by RNA polymerase II GO:0006357 10.17 TP53 MYC FOXA1 ESR1 ERBB2 EGFR
3 phosphorylation GO:0016310 10.16 SRC PIK3CA MTOR FGFR2 ERBB2 EGFR
4 cellular response to DNA damage stimulus GO:0006974 10.14 TP53 MYC CCND1 BRCA1 AKT1
5 positive regulation of cell proliferation GO:0008284 10.1 MYC FGFR2 ERBB2 EGFR CCND1 AR
6 cytokine-mediated signaling pathway GO:0019221 10.06 TP53 PIK3CA MYC CCND1 AKT1
7 negative regulation of gene expression GO:0010629 10.04 TP53 PGR MIR125A ESR1 AKT1
8 protein deubiquitination GO:0016579 10.03 TP53 MYC ESR1 BRCA1 AR
9 cell proliferation GO:0008283 10.02 TP53 SRC EGFR AR AKT1
10 regulation of cell proliferation GO:0042127 10.01 TP53 SRC EGFR BRCA1
11 transcription initiation from RNA polymerase II promoter GO:0006367 9.99 PGR ESR1 CCND1 AR
12 positive regulation of protein phosphorylation GO:0001934 9.99 MTOR ERBB2 EGFR CCND1 AKT1
13 peptidyl-tyrosine phosphorylation GO:0018108 9.98 SRC FGFR2 ERBB2 EGFR
14 protein phosphorylation GO:0006468 9.97 SRC PIK3CA MTOR HSPB8 FGFR2 ERBB2
15 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.94 SRC FGFR2 ERBB2 EGFR
16 response to estradiol GO:0032355 9.92 FOXA1 ESR1 EGFR CCND1
17 cellular response to hypoxia GO:0071456 9.92 TP53 SRC MYC MTOR AKT1
18 positive regulation of cell growth GO:0030307 9.91 ERBB2 EGFR AKT1
19 positive regulation of translation GO:0045727 9.91 MYC MTOR ERBB2
20 protein autophosphorylation GO:0046777 9.91 SRC MTOR FGFR2 ERBB2 EGFR AKT1
21 positive regulation of transcription, DNA-templated GO:0045893 9.91 TP53 SRC NCOA3 MYC ESR1 EGFR
22 cellular response to growth factor stimulus GO:0071363 9.9 ERBB2 EGFR AKT1
23 cellular response to drug GO:0035690 9.9 TP53 MYC EGFR
24 positive regulation of transcription by RNA polymerase II GO:0045944 9.9 TP53 PGR NCOA3 MYC FOXA1 FGFR2
25 response to estrogen GO:0043627 9.89 ESR1 CCND1 BRCA1
26 wound healing GO:0042060 9.89 TP53 MTOR FGFR2 ERBB2 EGFR
27 positive regulation of MAP kinase activity GO:0043406 9.88 SRC ERBB2 EGFR
28 steroid hormone mediated signaling pathway GO:0043401 9.88 PGR ESR1 AR
29 positive regulation of smooth muscle cell proliferation GO:0048661 9.88 MTOR FGFR2 EGFR AKT1
30 T cell costimulation GO:0031295 9.87 SRC PIK3CA AKT1
31 positive regulation of fibroblast proliferation GO:0048146 9.86 MYC ESR1 EGFR
32 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.86 EGFR CCND1 AKT1
33 cellular response to epidermal growth factor stimulus GO:0071364 9.86 ERBB2 EGFR AKT1
34 cellular response to estradiol stimulus GO:0071392 9.85 NCOA3 ESR1 EGFR
35 androgen receptor signaling pathway GO:0030521 9.85 NCOA3 BRCA1 AR
36 activation of protein kinase B activity GO:0032148 9.84 SRC MTOR AKT1
37 epidermal growth factor receptor signaling pathway GO:0007173 9.84 SRC PIK3CA EGFR AKT1
38 phosphatidylinositol 3-kinase signaling GO:0014065 9.83 PIK3CA ERBB2 AKT1
39 cellular response to reactive oxygen species GO:0034614 9.81 TP53 SRC EGFR AKT1
40 regulation of ERK1 and ERK2 cascade GO:0070372 9.8 FGFR2 ERBB2 EGFR
41 uterus development GO:0060065 9.78 SRC ESR1 CYP19A1
42 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.78 SRC EGFR CCND1 AKT1
43 mammary gland alveolus development GO:0060749 9.77 ESR1 CCND1 AR
44 positive regulation of epithelial cell proliferation GO:0050679 9.77 MYC FGFR2 ERBB2 EGFR CCND1
45 negative regulation of macroautophagy GO:0016242 9.76 PIK3CA MTOR AKT1
46 ERBB2 signaling pathway GO:0038128 9.76 SRC PIK3CA ERBB2 EGFR
47 negative regulation of telomerase activity GO:0051974 9.74 TP53 SRC
48 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.74 TP53 ESR1
49 Leydig cell differentiation GO:0033327 9.74 CCND1 AR
50 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.73 TP53 EGFR

Molecular functions related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 10.15 SRC PIK3CA NCOA3 MTOR FGFR2 ERBB2
2 ATP binding GO:0005524 10.14 TP53 SRC PIK3CA MTOR FGFR2 ERBB2
3 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 10.05 TP53 PGR NCOA3 MYC FOXA1 ESR1
4 identical protein binding GO:0042802 10.02 TP53 PGR MTOR HSPB8 ESR1 ERBB2
5 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.99 TP53 PGR MYC ESR1 AR
6 chromatin binding GO:0003682 9.97 TP53 FOXA1 ESR1 EGFR AR
7 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.91 TP53 PGR MYC FOXA1 ESR1 AR
8 protein dimerization activity GO:0046983 9.88 NCOA3 MYC ERBB2 AR
9 transcription factor binding GO:0008134 9.88 TP53 MYC FOXA1 ESR1 CCND1 AR
10 protein kinase binding GO:0019901 9.87 TP53 SRC MTOR ESR1 EGFR CCND1
11 kinase activity GO:0016301 9.86 SRC PIK3CA MTOR FGFR2 ERBB2 EGFR
12 protein tyrosine kinase activity GO:0004713 9.78 SRC FGFR2 ERBB2 EGFR
13 ATPase binding GO:0051117 9.76 PGR ESR1 AR
14 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.73 FGFR2 ERBB2 EGFR
15 steroid hormone receptor activity GO:0003707 9.72 PGR ESR1 AR
16 nuclear receptor activity GO:0004879 9.7 PGR ESR1 AR
17 steroid binding GO:0005496 9.63 PGR ESR1 AR
18 protein kinase activity GO:0004672 9.56 SRC MTOR HSPB8 FGFR2 ERBB2 EGFR
19 nitric-oxide synthase regulator activity GO:0030235 9.33 ESR1 EGFR AKT1
20 enzyme binding GO:0019899 9.28 TP53 SRC PGR ESR1 EGFR CCND1
Sources

Sources for Estrogen-Receptor Positive Breast Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....